AbbVie Inc. (ETR:4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 341.33B |
| Revenue (ttm) | 54.41B |
| Net Income (ttm) | 4.09B |
| Shares Out | n/a |
| EPS (ttm) | 2.31 |
| PE Ratio | 83.38 |
| Forward PE | n/a |
| Dividend | 5.88 (3.09%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 795 |
| Average Volume | 899 |
| Open | 190.72 |
| Previous Close | 190.36 |
| Day's Range | 190.72 - 193.78 |
| 52-Week Range | 141.98 - 193.78 |
| Beta | 0.56 |
| RSI | 75.15 |
| Earnings Date | Jan 31, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of thi...
AbbVie Inc. (ABBV) Announces $4 Billion Senior Notes Offering
AbbVie Inc. (ABBV) Announces $4 Billion Senior Notes Offering
My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys
January saw solid investment activity with $1,500 in net capital added, primarily into Business Development Companies like Owl Rock Capital, Goldman Sachs BDC, and Blackstone Secured Lending Fund. Div...
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials.
AbbVie Appears Ready To Move Higher
How Is The Market Feeling About AbbVie?
AbbVie's (NYSE: ABBV) short percent of float has risen 3.88% since its last report. The company recently reported that it has 18.93 million shares sold short , which is 1.07% of all regular shares th...
The Big 3: ABBV, EA, CEG
Today's Big 3 focuses on companies that couldn't be more different, but @ProsperTradingAcademy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's...
AbbVie Names CEO Robert A. Michael as Next Chairman
AbbVie (NYSE: ABBV) has announced that its board of directors has unanimously elected Chief Executive Officer Robert A. Michael to take on the additional role of chairman, effective July 1, 2025. He w...
AbbVie: An Undervalued Dividend Aristocrat
Discover how AbbVie Inc.'s robust growth strategy, diverse portfolio, and consistent dividend hikes make it a resilient investment. Click for more on ABBV.
AbbVie Just Paid Investors: Here’s How Much They Received
AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 years. The post AbbVie Just Paid Investors: Here’s How Much They Received appea...
AbbVie Inc (ABBV) Appoints CEO Robert A. Michael as Chairman of the Board
AbbVie Inc (ABBV) Appoints CEO Robert A. Michael as Chairman of the Board
AbbVie appoints CEO Robert Michael as chairman
AbbVie (ABBV) has elected Chief Executive Officer Robert A. Michael to assume the additional position of chairman, effective July 1, 2025, the company said on Friday.
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has...
All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend...
AbbVie declares $1.64 dividend
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
On Wednesday, AbbVie Inc (NYSE: ABBV) and Xilio Therapeutics, Inc. (NASDAQ: XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunother...
Tech and healthcare stocks struggle as Tesla drives auto gains
Sector overview The US stock market experienced a turbulent day, with technology and healthcare sectors facing significant declines. The semiconductor industry led the downturn with notable stocks suc...
AbbVie and Xilio Therapeutics announce collaboration and option agreement
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio secures $52M upfront & may earn up to $2.1B.
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers' consultative and clinical skills Innovative curriculum will empower providers t...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor con...
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Goldman Sachs downgraded Regenxbio Inc (NASDAQ: RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offe...
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I high...
AbbVie Inc (ABBV) Announces FDA Approval of EMBLAVEO⢠for Treating Complicated ...
AbbVie Inc (ABBV) Announces FDA Approval of EMBLAVEO⢠for Treating Complicated Intra-Abdominal Infections